ArticleBiofilm2023
Article in Biofilm, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- A dual-index framework for cold atmospheric plasma dosing: A meta-analysis of parametric control from volumetric redox flux to redox homeostatic status.Redox biology · 2026Pooled it
- Cold Atmospheric Plasma Disrupts Microbial Wound Bioburden: In Vitro, Porcine MRSA Biofilm, and Clinical Fluorescence Evidence from Bench to Bedside.Biomedicines · 2026Article
- Biofilm sensitization to breakJournal of medical microbiology · 2026Article
- Optimizing and tailoring cold atmospheric plasma parameters forFrontiers in microbiology · 2026Article
- Understanding Heterogeneity and Tolerance of Dual Candida albicans-Staphylococcus aureus Biofilms to Cold Atmospheric Plasma and Antimicrobial Combinations.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Cold Plasma as a Revolutionary Antimicrobial Modality: A Multifaceted Weapon Against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- MixedJournal of fungi (Basel, Switzerland) · 2025Article
- Treatment of Clinically Important Bacteria With Cold Atmospheric Plasma.Microbial biotechnology · 2025Review
- Antimicrobial Activity of Cold Atmospheric Plasma on Bacterial Strains Derived from Patients with Diabetic Foot Ulcers.Journal of microbiology and biotechnology · 2024Article
- Eurobiofilms 2022: A translational perspective of biofilm-related persistent infections.Biofilm · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global clinical and socioeconomic impact of chronic wounds is substantial. The main difficulty that clinicians face during the treatment of chronic wounds is the risk of infection at the wound site. Infected wounds arise from an accumulation of microbial aggregates in the wound bed, leading to the formation of polymicrobial biofilms that can be largely resistant to antibiotic therapy. Therefore, it is essential for studies to identify novel therapeutics to alleviate biofilm infections. One innovative technique is the use of cold atmospheric plasma (CAP) which has been shown to possess promising antimicrobial and immunomodulatory properties. Here, different clinically relevant biofilm models will be treated with cold atmospheric plasma to assess its efficacy and killing effects. Biofilm viability was assessed using live dead qPCR, and morphological changes associated with CAP evaluated using scanning electron microscopy (SEM). Results indicated that CAP was effective against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.